
June 16 (Reuters) - Lantern Pharma Inc LTRN.O:
LUNG CANCER PATIENT IN LANTERN PHARMA’S HARMONIC TRIAL SHOWS DURABLE COMPLETE RESPONSE IN TARGET CANCER LESIONS WITH SURVIVAL CONTINUING FOR NEARLY TWO YEARS
LANTERN PHARMA INC - NO SIGNIFICANT ADVERSE DRUG REACTIONS OVER 21 CYCLES OF TREATMENT
LANTERN PHARMA: ANTICIPATES ADDITIONAL DATA UPDATE FROM RANDOMIZED EXPANSION PHASE IN H2 2025